Divi's Lab slips after Q2 results

Divi's Laboratories fell 0.93% to Rs 1,139.25 at 9:21 IST on BSE after net profit rose 28.78% to Rs 295.73 crore on 17.12% increase in total income to Rs 993.96 crore in Q2 September 2015 over Q2 September 2014.

The result was announced on Saturday, 31 October 2015.

Meanwhile, the BSE Sensex was down 55.25 points, or 0.21%, to 26,601.58.

On BSE, so far 2,521 shares were traded in the counter, compared with an average volume of 71,900 shares in the past one quarter.

The stock hit a high of Rs 1,164 and a low of Rs 1,122.35 so far during the day. The stock hit a record high of Rs 1,241.80 on 21 August 2015. The stock hit a 52-week low of Rs 786.60 on 9 February 2015.

The stock had outperformed the market over the past one month till 30 October 2015, rising 3.16% compared with 1.92% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 19.28% as against Sensex's 3.78% decline.

The large-cap company has an equity capital of Rs 53.09 crore. Face value per share is Rs 2.

Forex gain amounted to Rs 12 crore in Q2 September 2015 as against a gain of Rs 4 crore in Q2 September 2014, Divi's Laboratories said in a statement.

Divi's Laboratories is primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) & intermediates for generics, custom synthesis of API's and advanced intermediates for discovery compounds for pharma giants, building blocks for peptides, building blocks for nucleotides, carotenoids and chiral ligands.

Powered by Capital Market - Live News